89bio, Inc. (ETNB) Bundle
An Overview of 89bio, Inc. (ETNB)
General Summary of 89bio, Inc. (ETNB)
89bio, Inc. was formed as a Delaware corporation in June 2019, continuing the business of 89Bio Ltd., which was incorporated in Israel in January 2018. The company focuses on developing therapies for metabolic and liver diseases, primarily its lead product candidate, pegozafermin, a glycoPEGylated long-acting FGF21 analog.
As of 2024, 89bio has been engaged in extensive research and development activities, including conducting Phase 3 clinical trials for pegozafermin, which aims to treat nonalcoholic steatohepatitis (NASH) and other metabolic disorders. The company has secured partnerships for manufacturing and supply, further enhancing its operational capabilities.
In terms of sales, the company reported no revenue from commercial products as of 2024, as its product candidates are still in the clinical trial phase.
Company's Financial Performance in the Latest Financial Reports
For the nine months ended September 30, 2024, 89bio reported a net loss of $248.7 million, compared to a net loss of $102.0 million for the same period in 2023. The substantial increase in net loss was primarily driven by heightened research and development expenses, which totaled $233.7 million, up from $88.6 million in the prior year.
Operating expenses for the nine months ended September 30, 2024, were broken down as follows:
| Operating Expense Category | 2024 (in thousands) | 2023 (in thousands) | Change (in thousands) |
|---|---|---|---|
| Research and Development | $233,734 | $88,638 | $145,096 |
| General and Administrative | $28,917 | $21,360 | $7,557 |
| Total Operating Expenses | $262,651 | $109,998 | $152,653 |
Additionally, the company reported interest income of $18.5 million for the nine months ended September 30, 2024, up from $12.0 million in 2023, while interest expense rose slightly to $4.1 million from $3.9 million. As of September 30, 2024, 89bio had cash, cash equivalents, and marketable securities totaling $423.8 million.
Introduction to 89bio as a Leader in the Industry
89bio, Inc. is positioned as a promising leader in the biotechnology sector, particularly in the field of metabolic and liver diseases. The company's innovative approach to developing pegozafermin showcases its commitment to addressing significant unmet medical needs within this therapeutic area.
With a robust pipeline of clinical trials and partnerships for manufacturing, 89bio is well-equipped to advance its products through the development process. The company's strategic focus on securing funding through public offerings and ATM facilities highlights its proactive approach to financing ongoing research and operational needs.
As of September 30, 2024, 89bio had an accumulated deficit of $706.2 million, reflecting its investment in research and development aimed at bringing novel therapies to market.
Mission Statement of 89bio, Inc. (ETNB)
Mission Statement of 89bio, Inc. (ETNB)
The mission statement of 89bio, Inc. emphasizes its commitment to developing innovative therapeutics for patients suffering from liver and metabolic diseases. The statement guides the company’s long-term goals, focusing on the development of its lead product, pegozafermin, and ensuring high-quality delivery of healthcare solutions.
Core Component 1: Innovation
At the heart of 89bio's mission is a strong emphasis on innovation. The company aims to leverage cutting-edge research and technology to advance its therapeutic candidates. For instance, as of September 30, 2024, 89bio reported a substantial increase in research and development expenses, totaling $233.7 million for the nine months ended, a rise of $145.1 million compared to the same period in 2023.
Core Component 2: Patient-Centric Approach
89bio's mission underscores a patient-centric approach, aiming to address unmet medical needs in liver and metabolic diseases. The company is currently conducting two Phase 3 clinical trials, ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis, to evaluate pegozafermin's efficacy. This commitment is further illustrated by the company's accumulated deficit of $706.2 million as of September 30, 2024, reflecting its ongoing investment in clinical development.
Core Component 3: Quality and Compliance
Quality and compliance form a critical part of 89bio's mission. The company is focused on meeting regulatory standards while developing its products. As part of its financial strategy, 89bio has engaged in various funding activities, including a public offering in December 2023, raising net proceeds of $161.8 million. This financial backing is essential for ensuring that the company adheres to the highest quality standards in its product development efforts.
| Financial Metric | 2024 (9 Months Ended) | 2023 (9 Months Ended) | Change |
|---|---|---|---|
| Research and Development Expenses | $233.7 million | $88.6 million | $145.1 million increase |
| Net Loss | $248.7 million | $102.0 million | $146.7 million increase |
| Cash, Cash Equivalents, and Marketable Securities | $423.8 million | $361.3 million | $62.5 million increase |
| Accumulated Deficit | $706.2 million | $547.2 million | $159.0 million increase |
| Net Proceeds from Public Offerings | $161.8 million | N/A | N/A |
Vision Statement of 89bio, Inc. (ETNB)
Vision Statement Overview
As of 2024, 89bio, Inc. (ETNB) is focused on addressing unmet medical needs in the treatment of metabolic diseases, particularly through its lead product candidate, pegozafermin, a long-acting FGF21 analog. The company envisions transforming the treatment landscape for patients with liver diseases and obesity-related conditions.
Commitment to Innovation
89bio aims to advance its research and development efforts to deliver innovative therapies. The company has significantly increased its research and development expenses, which totaled $233.7 million for the nine months ended September 30, 2024, compared to $88.6 million for the same period in 2023, reflecting a change of $145.1 million.
| Period | R&D Expenses (in $ thousands) | Change from Previous Year (in $ thousands) |
|---|---|---|
| 2024 (9 months) | 233,734 | 145,096 |
| 2023 (9 months) | 88,638 | - |
Patient-Centric Approach
89bio is dedicated to improving patient outcomes by developing therapies that are not only effective but also safe and accessible. The company has initiated two Phase 3 clinical trials in 2024, ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis, which are critical for evaluating the efficacy of pegozafermin in patients with liver diseases.
Global Reach and Collaboration
89bio's vision includes expanding its global footprint through strategic collaborations. In April 2024, the company entered a collaboration agreement with BiBo Biopharma Engineering Co., Ltd. to construct a production facility specifically for pegozafermin, enhancing its manufacturing capabilities.
Financial Stability and Growth
As of September 30, 2024, 89bio reported cash, cash equivalents, and marketable securities totaling $423.8 million, ensuring sufficient liquidity to support ongoing operations and development initiatives. The accumulated deficit stood at $706.2 million, indicating the company's extensive investment in research and development to realize its vision.
Future Outlook
89bio is poised for growth, with plans to leverage its financial resources and innovative pipeline to address significant unmet needs in metabolic disease treatment. The company’s focus on advancing clinical trials and enhancing production capabilities underscores its commitment to fulfilling its vision of becoming a leader in metabolic disease therapies.
Core Values of 89bio, Inc. (ETNB)
Core Value: Innovation
Innovation is a cornerstone of 89bio, Inc.'s operations, driving the company to develop cutting-edge therapies for liver and cardio-metabolic diseases. In 2024, the company has significantly advanced its lead product candidate, pegozafermin, which is engineered to treat metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).
For instance, 89bio reported a 145.1% increase in research and development expenses, totaling $233.7 million for the nine months ended September 30, 2024, compared to $88.6 million for the same period in 2023. This increase was primarily due to enhanced contract manufacturing costs and the initiation of two Phase 3 clinical trials.
Core Value: Collaboration
Collaboration is essential for 89bio's strategy to ensure the successful development and commercialization of its therapies. In April 2024, the company entered into a collaboration agreement with BiBo Biopharma Engineering Co., Ltd. to construct a dedicated production facility for pegozafermin. This facility is expected to meet the commercial supply needs of the drug if approved.
As part of its collaborative efforts, 89bio's clinical trials have shown promising results, with the FDA granting Breakthrough Therapy Designation to pegozafermin for MASH patients, indicating the importance of partnerships in achieving clinical milestones.
Core Value: Integrity
Integrity underpins 89bio's commitment to transparency and ethical practices in all its operations. The company maintains rigorous standards for data integrity in its clinical trials, evidenced by the positive topline results from the Phase 2b ENLIVEN trial of pegozafermin, which were presented with high statistical significance.
Furthermore, 89bio reported an accumulated deficit of $706.2 million as of September 30, 2024, reflecting the company's commitment to investing in its pipeline while maintaining transparency with stakeholders regarding its financial status.
Core Value: Accountability
Accountability is a vital value at 89bio, ensuring that all team members are responsible for their contributions to the company's goals. The company's financial reports indicate a significant focus on managing operational losses, with a net loss of $248.7 million for the nine months ended September 30, 2024, compared to $102.0 million for the same period in 2023.
89bio's management has committed to rigorous financial oversight, as evidenced by an increase in general and administrative expenses by 35.4% to $28.9 million in the same reporting period.
Core Value: Excellence
Excellence is reflected in 89bio's pursuit of high-quality research and development practices. The company has reported substantial investments in clinical trials, which are critical for the advancement of pegozafermin. The total operating expenses for the nine months ended September 30, 2024, reached $262.7 million, emphasizing the company’s commitment to excellence in its development efforts.
Moreover, 89bio’s strategic focus on achieving regulatory milestones, such as the Priority Medicines (PRIME) designation granted by the EMA, underscores its pursuit of excellence within the biopharmaceutical industry.
| Core Value | Key Metrics | Examples |
|---|---|---|
| Innovation | $233.7 million R&D expenses (2024) | Initiation of Phase 3 trials for pegozafermin |
| Collaboration | Breakthrough Therapy Designation (FDA) | Collaboration with BiBo for production facility |
| Integrity | $706.2 million accumulated deficit | Transparency in clinical trial data |
| Accountability | $248.7 million net loss (2024) | Increased oversight in operational expenses |
| Excellence | $262.7 million total operating expenses | Achieving PRIME designation from EMA |
89bio, Inc. (ETNB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- 89bio, Inc. (ETNB) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of 89bio, Inc. (ETNB)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View 89bio, Inc. (ETNB)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.